Alzheimer’s Association Welcomes Aduhelm Price Cut, But Presses On

Alzheimer’s Association Welcomes Aduhelm Price Cut, But Presses On

315159

Alzheimer’s Association Welcomes Aduhelm Price Cut, But Presses On

While calling the recent decision to slash by about half the U.S. list price for Aduhelm (aducanumab) an “important step,” the Alzheimer’s Association continues to advocate for more equitable access to the first new Alzheimer’s therapy since 2003. Specifically, the organization is calling for Biogen, which with Eisai developed and markets Aduhelm, to extend support to early-stage patients whose access to the treatment may still be limited by its cost. It also continues to urge the Centers for Medicare…

You must be logged in to read/download the full post.